Abstract
The FDA’s approval of milnacipran reflects advances in the development of drugs aimed at modulating pain circuitry in fibromyalgia.
Original language | English (US) |
---|---|
Pages (from-to) | 188-190 |
Number of pages | 3 |
Journal | Nature Reviews Rheumatology |
Volume | 5 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2009 |
ASJC Scopus subject areas
- Rheumatology